Cellectis S.A. (CLLS)Healthcare | Biotechnology | Paris, France | NasdaqGM
2.90 USD
-0.09
(-3.010%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 2.93 +0.04 (1.475%) ⇧ (July 13, 2026, 4:04 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:28 a.m. EDT
The investment case here is fractured by a brutal multi-year decline that fundamentally undermines any long-term thesis. Despite the company's impressive free cash flow and a fortress-like gross margin of 100%, the business has been decimated by a relentless downward trend, with five consecutive years of negative annual returns and a staggering 93.8% drop in share price over the last nine years. This trajectory suggests the market views the current operations as a value trap or a deteriorating asset, rendering the attractive free cash flow irrelevant without a proven path to profitability or massive scale. While recent headlines regarding FDA therapy designations and a post-earnings rally offer a glimmer of hope for a turnaround, the stock remains deeply distressed with negative earnings, a shrinking revenue base, and a balance sheet burdened by debt relative to equity. For the short term, the recent 24% rally and positive analyst targets create a speculative entry point, but the lack of a dividend and the structural damage to the business make this a high-risk gamble rather than a sound investment. |
| Model | MAE |
|---|---|
| MSTL_84_115 ✓ | 0.066544 |
| MSTL_115 | 0.117275 |
| MSTL_84 | 0.127939 |
| AutoTheta | 0.171767 |
| AutoARIMA | 0.185034 |
| AutoETS | 0.185037 |
| MSTL | 0.191399 |
Forecast horizon: 60 days | Selected: MSTL_84_115
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 5.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.082 |
| Excess Kurtosis | -1.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 137.408 |
| Revenue per Share | 0.748 |
| Market Cap | 292,024,672 |
| Forward P/E | -4.68 |
| Beta | 2.77 |
| Profit Margins | -89.51% |
| Website | https://www.cellectis.com |
As of July 11, 2026, 6:28 a.m. EDT: Speculators are positioning for a moderate rebound rather than a crash, evidenced by significant open interest in out-of-the-money calls at the $5.00 strike across multiple expirations. However, this bullish sentiment is heavily counterbalanced by substantial put volume at the $5.00 strike and deep in-the-money puts at lower strikes, indicating a 'straddle' or 'strangle' strategy where traders are betting on volatility expansion rather than a specific directional move. The implied volatility skew suggests fear of further downside is priced in, yet the call activity hints at hopes for a recovery driven by the recent FDA designations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.39069772 |
| Address1 | 8, rue de la Croix Jarry |
| All Time High | 50.0 |
| All Time Low | 0.963 |
| Ask | 3.2 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 16,530 |
| Average Daily Volume3 Month | 33,811 |
| Average Volume | 33,811 |
| Average Volume10Days | 16,530 |
| Beta | 2.765 |
| Bid | 2.89 |
| Bid Size | 1 |
| Book Value | 0.825 |
| City | Paris |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.9 |
| Current Ratio | 1.521 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.99 |
| Day Low | 2.87 |
| Debt To Equity | 137.408 |
| Display Name | Cellectis |
| Earnings Call Timestamp End | 1,774,008,000 |
| Earnings Call Timestamp Start | 1,774,008,000 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -32,749,000 |
| Ebitda Margins | -0.436 |
| Enterprise To Ebitda | -3.281 |
| Enterprise To Revenue | 1.431 |
| Enterprise Value | 107,456,424 |
| Eps Forward | -0.62 |
| Eps Trailing Twelve Months | -0.65 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.38106 |
| Fifty Day Average Change | -0.4810598 |
| Fifty Day Average Change Percent | -0.14228077 |
| Fifty Two Week Change Percent | 39.06977 |
| Fifty Two Week High | 5.48 |
| Fifty Two Week High Change | -2.58 |
| Fifty Two Week High Change Percent | -0.4708029 |
| Fifty Two Week Low | 1.62 |
| Fifty Two Week Low Change | 1.2800001 |
| Fifty Two Week Low Change Percent | 0.7901235 |
| Fifty Two Week Range | 1.62 - 5.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,427,203,800,000 |
| Float Shares | 46,690,988 |
| Forward Eps | -0.62 |
| Forward P E | -4.6774197 |
| Free Cashflow | 91,416,496 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 224 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 75,112,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.16539 |
| Implied Shares Outstanding | 100,698,158 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. |
| Long Name | Cellectis S.A. |
| Market | us_market |
| Market Cap | 292,024,672 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1216695 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -67,230,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 297,008,518 |
| Number Of Analyst Opinions | 5 |
| Open | 3.06 |
| Operating Cashflow | -37,651,000 |
| Operating Margins | -3.33426 |
| Payout Ratio | 0.0 |
| Phone | 33 1 81 69 16 00 |
| Post Market Change | 0.042600155 |
| Post Market Change Percent | 1.4753811 |
| Post Market Price | 2.93 |
| Post Market Time | 1,783,973,091 |
| Previous Close | 2.99 |
| Price Hint | 4 |
| Price To Book | 3.5151517 |
| Price To Sales Trailing12 Months | 3.8878565 |
| Profit Margins | -0.89505994 |
| Quick Ratio | 1.491 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.089999914 |
| Regular Market Change Percent | -3.0100307 |
| Regular Market Day High | 2.99 |
| Regular Market Day Low | 2.87 |
| Regular Market Day Range | 2.87 - 2.99 |
| Regular Market Open | 3.06 |
| Regular Market Previous Close | 2.99 |
| Regular Market Price | 2.9 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 27,573 |
| Return On Assets | -0.084309995 |
| Return On Equity | -0.76344 |
| Revenue Growth | -0.373 |
| Revenue Per Share | 0.748 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 72,698,158 |
| Shares Percent Shares Out | 0.0032 |
| Shares Short | 321,876 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 352,107 |
| Short Name | Cellectis S.A. |
| Short Percent Of Float | 0.0058 |
| Short Ratio | 6.57 |
| Source Interval | 15 |
| Symbol | CLLS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.6 |
| Target Median Price | 8.0 |
| Total Cash | 185,424,000 |
| Total Cash Per Share | 2.554 |
| Total Debt | 82,335,000 |
| Total Revenue | 75,112,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.81484 |
| Two Hundred Day Average Change | -0.91484 |
| Two Hundred Day Average Change Percent | -0.23981084 |
| Type Disp | Equity |
| Volume | 27,573 |
| Website | https://www.cellectis.com |
| Zip | 75,013 |